ORYZON Publishes Paper in ACS Pharmacology & Translational Science Supporting Best-in-Class Performance of Iadademstat in Oncology

NEXT STORY
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021
PREV STORY
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CB2 Insights Announces Acquisition of Texas-based Primary Care Medical & Wellness Clinic with $1.6 million in Revenue and Positive EBITDA

author_avatar
NASDAQ Market News

New Drug Application Submitted in Japan for INTUNIV® (guanfacine hydrochloride extended release) in Adults with ADHD

New Drug Application Submitted in Japan for INTUNIV® (guanfacine hydrochloride extended release) in Adults ...

author_avatar
NASDAQ Market News

Biocartis Group NV: BIOCARTIS Q1 2018 BUSINESS UPDATE

author_avatar
NASDAQ Market News